Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Influence of liraglutide, dulaglutide versus conventional treatment on fatty liver index and fibrosis-4 score in Egyptian patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease
However, one challenge is that stopping the drug can lead to weight gain
Therefore, patients must remain in close communication with their providers regarding treatment continuity
"That broader availability though still limited may be what's driving GLP-1 usage higher overall." Related: Goldman Sachs doubles down on Novo stock target after key event This story was originally published by TheStreet on Jul 8, 2026, where it first appeared in the Health section
US$ 25.82
US$ 22.08
US$ 21.02
